A Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Primary Osteoarthritis of the Hip
Public ClinicalTrials.gov record NCT01618708. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Pivotal, Multicenter, Double Blind Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Mild to Moderate Primary Osteoarthritis of the Hip
Study identification
- NCT ID
- NCT01618708
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Not applicable
- Lead sponsor
- Genzyme, a Sanofi Company
- Industry
- Enrollment
- 357 participants
Conditions and interventions
Conditions
Interventions
- Synvisc-One (hylan G-F 20) Device
- Placebo Device
Device
Eligibility (public fields only)
- Age range
- 35 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 31, 2012
- Primary completion
- May 31, 2015
- Completion
- May 31, 2015
- Last update posted
- Jul 10, 2016
2012 – 2015
United States locations
- U.S. sites
- 45
- U.S. states
- 24
- U.S. cities
- 44
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Investigational Site Number 840025 | Burmingham | Alabama | 35216 | — |
| Investigational Site Number 840042 | Phoenix | Arizona | 85016 | — |
| Investigational Site Number 840056 | Phoenix | Arizona | 85027 | — |
| Investigational Site Number 840004 | Tucson | Arizona | 85712 | — |
| Investigational Site Number 840023 | Covina | California | 91723 | — |
| Investigational Site Number 840058 | La Mesa | California | 91942 | — |
| Investigational Site Number 840022 | Santa Monica | California | 90904 | — |
| Investigational Site Number 840050 | Farmington | Connecticut | 06033 | — |
| Investigational Site Number 840027 | Stamford | Connecticut | 06905 | — |
| Investigational Site Number 840051 | Waterbury | Connecticut | 06708 | — |
| Investigational Site Number 840011 | Bradenton | Florida | 84020 | — |
| Investigational Site Number 840036 | Fort Lauderdale | Florida | 33316 | — |
| Investigational Site Number 840017 | Jupiter | Florida | 33458 | — |
| Investigational Site Number 840038 | New Port Richey | Florida | 34652 | — |
| Investigational Site Number 840041 | Pensacola | Florida | 32504 | — |
| Investigational Site Number 840047 | Sarasota | Florida | 34232 | — |
| Investigational Site Number 840049 | South Miami | Florida | 33134 | — |
| Investigational Site Number 840039 | Marietta | Georgia | 30060 | — |
| Investigational Site Number 840005 | Meridian | Idaho | 83642 | — |
| Investigational Site Number 840002 | Chicago | Illinois | 60611 | — |
| Investigational Site Number 840043 | Wichita | Kansas | 67203 | — |
| Investigational Site Number 840012 | Lexington | Kentucky | 40509 | — |
| Investigational Site Number 840033 | Traverse City | Michigan | 49648 | — |
| Investigational Site Number 840037 | St Louis | Missouri | 63128 | — |
| Investigational Site Number 840007 | Reno | Nevada | 89502 | — |
| Investigational Site Number 840048 | Egg Harbor | New Jersey | 08234 | — |
| Investigational Site Number 840024 | Amherst | New York | 14226 | — |
| Investigational Site Number 840029 | Hartsdale | New York | 10530 | — |
| Investigational Site Number 840014 | Rochester | New York | 14609 | — |
| Investigational Site Number 840044 | Asheville | North Carolina | 28801 | — |
| Investigational Site Number 840028 | Raleigh | North Carolina | 27612 | — |
| Investigational Site Number 840045 | Wilmington | North Carolina | 28401 | — |
| Investigational Site Number 840046 | Columbus | Ohio | 43213 | — |
| Investigational Site Number 840013 | Altoona | Pennsylvania | 16635 | — |
| Investigational Site Number 840055 | Philadelphia | Pennsylvania | 19107 | — |
| Investigational Site Number 840018 | Reading | Pennsylvania | 19611 | — |
| Investigational Site Number 840026 | Mt. Pleasant | South Carolina | 29464 | — |
| Investigational Site Number 840052 | Memphis | Tennessee | 38163 | — |
| Investigational Site Number 840054 | Austin | Texas | 78751 | — |
| Investigational Site Number 840040 | Bedford | Texas | 76021 | — |
| Investigational Site Number 840010 | Dallas | Texas | 75235 | — |
| Investigational Site Number 840009 | Draper | Utah | 84020 | — |
| Investigational Site Number 840032 | Salt Lake City | Utah | 84107 | — |
| Investigational Site Number 840016 | Charlottesville | Virginia | 22901 | — |
| Investigational Site Number 840003 | Seattle | Washington | 98166 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 3 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01618708, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 10, 2016 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01618708 live on ClinicalTrials.gov.